Literature DB >> 3080099

Effective short term treatment of Paget's disease with oral etidronate.

C J Preston, A J Yates, M N Beneton, R G Russell, R E Gray, R Smith, J A Kanis.   

Abstract

Twelve patients with Paget's disease of bone were treated with high doses of disodium etidronate for one month and compared with patients given treatments for longer periods. The effects of treatment for one month with etidronate 20 mg/kg daily were indistinguishable from six months' continuous treatment with the same dose but significantly better than treatment with 5 mg/kg daily in suppressing biochemical indices of disease activity. Treatment for one month was associated with transient osteomalacia but sustained suppression of bone resorption. Short term treatments with high doses of disodium etidronate may maximise suppression of disease activity but decrease exposure to unwanted effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080099      PMCID: PMC1339104          DOI: 10.1136/bmj.292.6513.79

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  7 in total

1.  Diphosphonates in Paget's disease.

Authors:  R G Russell; R Smith; C Preston; R J Walton; C G Woods
Journal:  Lancet       Date:  1974-05-11       Impact factor: 79.321

2.  Diphosphonates and inhibition of bone mineralization.

Authors:  C Nagant de Deuxchaisnes; C Rombouts-Lindemans; J P Huaux; J P Devogelaer
Journal:  Lancet       Date:  1982-09-11       Impact factor: 79.321

3.  Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.

Authors:  A J Yates; R C Percival; R E Gray; R M Atkins; G H Urwin; N A Hamdy; C J Preston; M N Beneton; R G Russell; J A Kanis
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

4.  Monitoring the treatment of Paget's disease with etidronate.

Authors:  J A Kanis
Journal:  Calcif Tissue Int       Date:  1984-12       Impact factor: 4.333

5.  Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

Authors:  R D Altman; C C Johnston; M R Khairi; H Wellman; A N Serafini; R R Sankey
Journal:  N Engl J Med       Date:  1973-12-27       Impact factor: 91.245

6.  Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man.

Authors:  R J Walton; R G Russell; R Smith
Journal:  Clin Sci Mol Med       Date:  1975-07

7.  Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease.

Authors:  B F Boyce; L Smith; I Fogelman; E Johnston; S Ralston; I T Boyle
Journal:  Lancet       Date:  1984-04-14       Impact factor: 79.321

  7 in total
  10 in total

Review 1.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Short term high doses of etidronate in Paget's disease of bone.

Authors:  J A Kanis; R E Gray; S A Murray; N A Hamdy; G H Urwin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-21

3.  Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate.

Authors:  C J Gibbs; J E Aaron; M Peacock
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-10

Review 4.  Treating Paget's disease.

Authors:  D A Heath
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-25

5.  Treating Paget's disease.

Authors:  J A Kanis; R E Gray; E V McCloskey
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-20

6.  The effect of two different doses of oral clodronate on pain in patients with bone metastases.

Authors:  A Arican; F Içli; H Akbulut; M Cakir; O Sencan; M Samur; N Açikgöz; A Demirkazik
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

Review 7.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 8.  Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  C J Dunn; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

Review 9.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

10.  Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.

Authors:  N P O'Rourke; E V McCloskey; S Vasikaran; K Eyres; D Fern; J A Kanis
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.